Investor Presentaiton

27 Innovative R&D - Small Molecule Core Pipeline Therapeutic Area Project Target/MOA Indication FCN-437c CDK4/6 Breast cancer (1L) Breast cancer (2L) ALK Non-small cell lung cancer SAF-189 ROS1 Non-small cell lung cancer HLX-208 BRAF V600E Solid tumors (metastatic colorectal cancer, non-small cell lung cancer, etc.) LCH and ECD5 Neurofibromatosis type 1 Low-grade glioma FCN-159 MEK Malignant melanoma Pre-Clinical IND Phase 1 Phase 2 Phase 3 NDA Approved to enter Phase 3 clinical trial by NMPA in January 2022; Phase 1 clinical trial in the U.S. Approved to enter Phase 3 clinical trial by NMPA in January 2022; Phase 1 clinical trial in the U.S. Initiated Phase 3 clinical trial in Chinese Mainland in January 2022; approved to enter clinical trials by FDA Approved to enter clinical trials by FDA Approved to enter Phase 1b/Phase 2 clinical trials by NMPA in January 2022 Global multi-center clinical trial Anti-tumor ORIN1001 YP01001 Arteriovenous malformation Histiocytic tumor Solid tumor VEGFR Advanced solid tumor FGFR/PD- L1 Hematological malignancies Relapsed or refractory B-cell lymphoma Advanced malignant solid tumors FCN-3381 Lilly BCL-2 FH-2001 PLK1 Inhibitor PLK1 KRAS mutations in colorectal and non-small cell lung cancer CHK1 Inhibitor CHK1 Ovarian cancer and other solid tumors IRAK4/BTK DLBCL Approved to enter clinical trial by NMPA in May 2022 Approved to enter clinical trial by NMPA in May 2022 Approved Phase 1 clinical trial in the U.S. Approved Phase 1 clinical trial in the U.S.. Approved to enter Phase 1 clinical trial by NMPA in October 2021 Approved to enter Phase 1 clinical trial by NMPA in August 2021 IRAK4/BTK Inhibitor Note 1: granted Lilly exclusive right to develop, manufacture and commercialize in all countries and regions excluding Chinese Mainland, Macau and Hong Kong Note 2: last update on 29th August 2022

View entire presentation